Tradestie Institutional Equity Comparison Engine

ENSC vs CLYM โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CLYM Overall Edge

CLYM Captures Institutional Edge (2โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Climb Bio, Inc. Common Stock (CLYM) driven by superior Growth & Margin, Momentum & Technical while ENSC counters with relative strength in Valuation. Fundamentally, ENSC trades at 0.8x Forward P/E with -281.3% operating margin (-15.1% YoY revenue) versus CLYM at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ENSC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CLYM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner ENSC
ENSC 0.8x vs CLYM N/M Fwd P/E
Growth & Margin Winner CLYM
Op Margin -281.3% vs 0.0% ยท YoY -15.1% vs +0.0%
Momentum & Technical Winner CLYM
1Y -80.3% vs +399.5% ยท 52W Pos 8% vs 45%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
ENSC NASDAQ
Ensysce Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$0.36
-0.17% 1D
Market Cap $7.0M
1M Return -29.55%
1Y Return -80.33%
Forward P/E 0.8x
Unified AI Score
53.4 / 100 HOLD
Tech 50.0 Fund 62.0 Flow 50.0 Mom 60.0
CLYM NASDAQ
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.19
-0.97% 1D
Market Cap $545.1M
1M Return -12.81%
1Y Return +399.46%
Forward P/E N/M
Unified AI Score
43.7 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ENSC -80.33% CLYM +399.46% Spread: +479.79 pp (CLYM Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ENSC TTM Op. Margin: -281.3% CLYM TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ENSC vs CLYM. Trailing 12-month operating profitability (ENSC -281.3% vs CLYM 0.0%) and valuation multiples (ENSC 0.8x vs CLYM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ENSC (4) vs CLYM (6)
Institutional Metric ENSC CLYM Criterion Row Winner
Market Capitalization Scale $7.0M $545.1M Larger Scale CLYM
Trailing P/E Ratio Valuation 0.8x N/M Lower Multiple ENSC
Forward P/E Ratio Valuation 0.8x N/M Lower Multiple ENSC
Revenue Growth (YoY) Growth -15.1% +0.0% Higher Growth CLYM
Operating Margin (TTM) Profitability -281.3% 0.0% Higher Margin CLYM
Net Profit Margin Profitability -280.5% 0.0% Higher Margin CLYM
Return on Equity (ROE) Capital Efficiency -1295.1% -29.3% Higher ROE CLYM
52-Week Range Position Momentum 8% ($0โ€“$2) 45% ($2โ€“$18) Stronger Trend CLYM
Beta / 30D Volatility Risk Regime 0.98ฮฒ ยท 79% Vol 1.42ฮฒ ยท 106% Vol Lower Realized Risk ENSC
Unified Institutional Score Composite Signal 53.4 / 100 (HOLD) 43.7 / 100 (HOLD) Higher Composite ENSC

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ENSC vs CLYM Buy Guide
ENSC UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ENSC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CLYM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CLYM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ENSC nor CLYM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.